The oral c-Met inhibitor tivantinib missed its primary endpoint of improving overall survival vs. placebo in a phase III hepatocellular carcinoma (HCC) study, calling into question the future of the program, licensed by Arqule Inc. to Tokyo-based Daiichi Sankyo Group in December 2008, even as another phase III study of the candidate in Japan progresses. Shares in Arqule (NASDAQ:ARQL) fell 18.4 percent, closing at $1.20 on Friday.